| |  | Firm | Analyst | | Argus Research Company | Martha Freitag | | Atlantic Equities | Vasavi Vittal | | Barclays Capital | Jim Birchenough MD | | BMO Capital Markets | Jason Zhang PhD | | BWS Financial | Hamed Khorsand | | Citigroup | Yaron Werber MD | | Cowen & Company | Phil Nadeau PhD | | Credit Suisse | Michael Aberman MD | | Deutsche Bank | Mark Schoenebaum | | First Global Stockbroking Ltd. | Devina Mehra | | Jefferies & Company | Eun Yang PhD | | JPMorgan | Geoffrey Meacham PhD | | Lazard Capital Markets | Joel Sendek | | Leerink Swann & Co. | William Tanner PhD | | Merrill Lynch | David Risinger CFA | | Merriman Curhan Ford | Edward H. Nash | | Morgan Joseph | Shiv Kapoor | | Morgan Stanley | Sapna Srivastava PhD | | Natixis Bleichroeder | Alex To MD | | Needham | Alan Carr | | Oppenheimer | Bret Holley PhD | | Pacific Growth Equities | Timothy Wilson PhD | | Piper Jaffray & Co. | Thomas Wei | | RBC Capital Markets | Jason Kantor | | Robert W. Baird & Co | Thomas J. Russo CFA | | Rodman & Renshaw | Christopher James MD | | Sanford C. Bernstein & Co. | Geoffrey Porges PhD | | Stanford Group Company | Biren Amin | | Thomas Weisel Partners | M. Ian Somaiya | | UBS | Maged Shenouda | | Wachovia Capital Markets | Aaron Reames | | William Blair & Company | John Sonnier |
|
|
| Gilead Sciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Gilead Sciences's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Gilead Sciences or its management. Gilead Sciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
